Zohydro Approval Haunts FDA Panelist At Vantrela Meeting
Executive Summary
Teva's comparative data suggesting its Vantrela is less attractive to abusers validates advisory committee recommendation in 2012 against Zohydro's approval, advisory committee member says.
You may also be interested in...
Opana Withdrawal Request Builds On US FDA Actions On Palladone, OxyContin
Earlier withdrawals of Purdue’s Palladone and original OxyContin create precedent for request that Endo’s Opana ER come off market due to risk of abuse; former chief counsel sees agency's move as ‘tip of the iceberg’ on opioid safety actions.
FDA Clears Zohydro Single-Entity Hydrocodone Without Abuse Deterrence Properties
Advisory committee had recommended against approval before the agency imposed additional post-marketing study requirements on the extended-release/long-acting opioid class.
Tighter REMS For Zohydro ER Still Insufficient For FDA Advisory Panel
FDA’s Anesthetic and Analgesic Drug Products Advisory Committee wants Risk Evaluation and Mitigation Strategies enhanced for all extended-release/long-acting opioids as it recommends 11-2, one abstention, against approval of Zogenix’s single-entity hydrocodone product.